GRIFOLS SA-ADR (GRFS)
US3984384087 - ADR
GRIFOLS SA-ADR
NASDAQ:GRFS (11/29/2024, 3:33:10 PM)
After market: 6.99 0 (0%)6.99
-1.08 (-13.38%)
Company Profile
Grifols SA engages in the production of plasma derivatives. The company is headquartered in Sant Cugat Del Valles, Barcelona and currently employs 23,744 full-time employees. The company went IPO on 2006-05-17. The firm organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.
Company Info
GRIFOLS SA-ADR
Parque Empresarial Can Sant Joan, Avinguda de la Generalitat, 152-158
Sant Cugat del Valles BARCELONA 08174
P: 34935710000
CEO: Raimon Grifols Roura
Employees: 23505
Website: https://www.grifols.com/
GRFS News
2 days ago - ChartmillWednesday's pre-market session: top gainers and losersThe US market is yet to commence its session on Wednesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
a month ago - Grifols, S.A.Grifols Receives FDA Approval to Treat Surgical Bleeding in Pediatric Patients With its Fibrin Sealant SolutionYounger patients in the U.S. can now benefit from Grifols Fibrin Sealant (FS) and its positive effect on surgical outcomes, including a fast time to...
3 months ago - TheNewswire.comINVESTIGATION ALERT: Grifols SA Faces Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLPNEW YORK, NY - (NewMediaWire) - August 31, 2024 - Kaplan Fox & Kilsheimer LLP continues to investigate potential securities violations against Grifols SA (GRFS) (“Grifols” or the “Company”) (NASDAQ: GRFS).
3 months ago - NewMediaWireINVESTIGATION ALERT: Grifols SA Faces Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLPSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
3 months ago - TheNewswire.comGrifols SA is Being Investigated for Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLPNEW YORK, NY - (NewMediaWire) - August 29, 2024 - Kaplan Fox & Kilsheimer LLP continues to investigate potential securities violations against Grifols SA (GRFS) (“Grifols” or the “Company”) (NASDAQ: GRFS).
3 months ago - NewMediaWireGrifols SA is Being Investigated for Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLPSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GRFS Twits
Here you can normally see the latest stock twits on GRFS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
